Chemring (BC88) AI Stock Analysis

Compare

4 Followers

Top Page

Chemring

(LSE:BC88)

Rating:63Neutral

Price Target:

103.00p

▲(6.19% Upside)

Chemring shows strong financial performance with robust revenue growth and profitability, but technical indicators suggest the stock may be overbought. Valuation is neutral due to lack of data, while positive earnings call data is excluded from calculation due to weight distribution.

Chemring (BC88) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap

£1.45B

Dividend Yield7.22%

Average Volume (3M)1.76K

Price to Earnings (P/E)―

Beta (1Y)-9.54

Revenue GrowthN/A

EPS GrowthN/A

CountryUK

Employees2,786

SectorIndustrials

Sector Strength75

IndustryAerospace & Defense

Share Statistics

EPS (TTM)N/A

Shares Outstanding62,500

10 Day Avg. Volume1,762

30 Day Avg. Volume1,762

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£103.00

Price Target Upside6.19% Upside

Rating ConsensusHold

Number of Analyst Covering1

Chemring Business Overview & Revenue Model

Company DescriptionChemring Group PLC is a UK-based defense technology company that specializes in advanced manufacturing and engineering for defense and security markets. The company operates across several sectors, including munitions, countermeasures, explosive ordnance disposal, and sensing solutions. Chemring's core products and services include pyrotechnics, military training systems, and innovative technologies for defense applications, catering to both military and civilian markets globally.

How the Company Makes MoneyChemring generates revenue primarily through the sale of defense-related products and services. The company operates multiple segments, including Countermeasures, Munitions, and Sensors, each contributing to its overall revenue. Key revenue streams include long-term contracts with government defense departments, sales of military equipment and systems, and the provision of technical support and training services. Significant partnerships with military organizations and defense contractors enhance its market presence, while ongoing investments in research and development allow Chemring to innovate and expand its product offerings, ensuring a steady flow of income from both new and existing customers.

Chemring Earnings Call Summary

Earnings Call Date:Jun 03, 2025

(Q2-2025)

% Change Since: 0.00%|

Next Earnings Date:Dec 23, 2025

Earnings Call Sentiment Positive

The earnings call highlighted strong growth in order intake and revenue, significant advancements in the Countermeasures & Energetics segment, a robust market outlook, and promising innovation in electronic warfare. However, these positives were tempered by challenges in the Sensors & Information segment and Roke's order intake softness, along with some FX headwinds.

Q2-2025 Updates

Positive Updates

Record Order Intake

The company reported a record GBP 488 million of order intake, marking a 42% increase from the previous year, contributing to a record order book of GBP 1.3 billion.

Revenue and Profit Growth

Revenue increased by 5%, operating profit rose by 8%, and earnings per share grew by 3%, driven by strong performance in the Countermeasures & Energetics segment.

Countermeasures & Energetics Segment Performance

This segment saw a 20% revenue growth, a 73% increase in operating profit, and a margin increase to 14.4%.

Strong Cash Conversion

The company achieved a strong cash conversion at 80%, with GBP 46 million of CapEx spent, partially offset by GBP 13 million of grant funding.

Positive Market Environment

Global defense spending is rising, with increased demand for products due to geopolitical tensions and military developments.

Innovation in Electronic Warfare

The launch of the Deceive system in electronic warfare drew international interest from over 15 countries.

Negative Updates

Sensors & Information Segment Weakness

The segment experienced a 12% revenue decline and a 26% decrease in operating profit due to prior-year benefits and delays in U.K. government spending.

Roke's Softness in U.K. Order Intake

Roke experienced a softness in U.K. order intake, attributed to customer workload related to the Strategic Defense Review, leading to cost base adjustments.

FX Headwinds

A small foreign exchange headwind was noted, which affected the financial outcomes.

Company Guidance

In the call discussing Chemring's interim results for the first half of fiscal year 2025, several key metrics were highlighted. The company reported a record order intake of GBP 488 million, a 42% increase from the previous year, leading to an unprecedented order book of GBP 1.3 billion. Revenue increased by 5%, with operating profit up 8%, and earnings per share rising by 3%. The Countermeasures & Energetics segment saw revenue growth of 20%, while Sensors & Information experienced a 12% decline in revenue. The group's operating margin improved to 11.6%, and cash conversion remained strong at 80%. Capital expenditures totaled GBP 46 million, with significant investments in Energetics expansion projects. The company maintained a resilient balance sheet with closing net debt of GBP 93 million, targeting leverage of less than 1.5x. The guidance for fiscal year 2025 remained unchanged, with 85% of expected revenue already delivered or in the order book. The company is progressing towards its longer-term goal of achieving GBP 1 billion in annual revenue by 2030.

Chemring Financial Statement Overview

Summary

Chemring has demonstrated strong revenue growth and profitability with improved margins and cash generation capabilities. The company maintains a conservative financial structure with low leverage, but a decrease in free cash flow requires attention.

Income Statement

Very Positive

Chemring has demonstrated strong revenue growth, with a significant increase from the previous year, indicating a robust growth trajectory. The gross profit margin remains high at 100%, which is unusual and suggests all revenues translate directly into gross profit. The net profit margin has improved substantially from 1.14% to 7.74%, reflecting enhanced operational efficiency. Both EBIT and EBITDA margins have improved, indicating better core profitability and operational efficiency.

Balance Sheet

Positive

The company's balance sheet shows a healthy equity ratio of 51.49%, suggesting a strong reliance on equity financing. The debt-to-equity ratio stands at 0.27, indicating a conservative use of leverage. However, the return on equity has decreased, which may point to less efficient use of shareholder funds compared to previous periods.

Cash Flow

Positive

Chemring's operating cash flow has increased, showcasing improved cash-generating ability. However, free cash flow has decreased due to higher capital expenditures. The free cash flow to net income ratio has declined, suggesting that less net income is translating into free cash flow, which could impact future flexibility.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	510.40M	472.60M	442.80M	393.30M	402.50M
Gross Profit	510.40M	472.60M	442.80M	393.30M	402.50M
EBITDA	82.70M	67.70M	76.20M	75.50M	75.10M
Net Income	39.50M	5.40M	47.40M	41.50M	34.70M
Balance Sheet
Total Assets	692.10M	596.40M	620.10M	531.50M	541.40M
Cash, Cash Equivalents and Short-Term Investments	45.00M	6.40M	19.80M	5.80M	14.70M
Total Debt	97.70M	20.70M	26.90M	32.30M	62.80M
Total Liabilities	335.80M	217.90M	202.00M	178.70M	211.80M
Stockholders Equity	356.30M	378.50M	418.10M	352.80M	329.60M
Cash Flow
Free Cash Flow	11.40M	31.70M	46.00M	45.50M	35.10M
Operating Cash Flow	81.00M	65.90M	80.50M	75.70M	75.90M
Investing Cash Flow	-47.60M	-39.40M	-30.50M	-34.90M	-25.40M
Financing Cash Flow	-37.30M	-40.20M	-35.80M	-50.40M	-32.10M

Chemring Peers Comparison

Overall Rating

UnderperformOutperform

Sector (66)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNR	77 Outperform	£823.52M	23.68	8.19%	0.89%	-13.81%	13.86%
CHRT	76 Outperform	£594.27M	28.98	14.40%	1.21%	33.33%	15.05%
AVON	75 Outperform	£610.40M	120.39	4.18%	0.94%	14.69%	―
BA	66 Neutral	£51.96B	26.98	17.59%	1.88%	11.60%	8.03%
Sector *	66 Neutral	£2.68B	13.05	3.30%	3.25%	2.40%	-22.21%
BC88	63 Neutral	£1.45B	―		7.22%	―	―
QQ	63 Neutral	£2.62B	17.97	-23.92%	1.84%	1.02%	-240.44%

* Industrials Sector Average

Performance Comparison

GB:BC88

Chemring

97.00

0.00

0.00%

GB:BA

BAE Systems

1,760.00

449.24

34.27%

GB:AVON

Avon Technologies

1,990.00

748.32

60.27%

GB:SNR

Senior plc

198.40

30.77

18.36%

GB:CHRT

Cohort plc

1,264.00

417.69

49.35%

GB:QQ

QinetiQ

481.60

13.34

2.85%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 04, 2025